SPOTLIGHT: Renovis licensee expands Phase III trial


AstraZeneca, Renovis' exclusive licensee for Cerovive, a drug for stroke victims, has boosted planned enrollment in its Phase III trial to 3,200 patients from 1,700, resulting in a delay of up to one year in regulatory filing. AstraZeneca is adding at least 10 countries to the trial in hopes of increasing the rate of enrollment and cutting the time lag. Release

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.